These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34333000)

  • 1. Incretin-based therapies in 2021 - Current status and perspectives for the future.
    Rizzo M; Nauck MA; Mantzoros CS
    Metabolism; 2021 Sep; 122():154843. PubMed ID: 34333000
    [No Abstract]   [Full Text] [Related]  

  • 2. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The journey to understanding incretin systems: Theory, practice and more theory.
    Yabe D; Kuwata H; Seino Y
    J Diabetes Investig; 2019 Sep; 10(5):1171-1173. PubMed ID: 31361402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates of incretin-related drugs for the treatment of type 2 diabetes.
    Araki H; Matsumura T; Furukawa N; Araki E
    J Diabetes Investig; 2023 Feb; 14(2):189-192. PubMed ID: 36373430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
    Grunberger G
    J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms.
    Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
    Oxid Med Cell Longev; 2021; 2021():9959320. PubMed ID: 34007411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-based therapies: facing the realities of benefits versus side effects.
    Lebovitz HE
    Diabetes Technol Ther; 2013 Nov; 15(11):909-13. PubMed ID: 24111860
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent advances in incretin-based therapies.
    Russell-Jones D; Gough S
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
    Garber AJ
    Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Not only incretins for diabetic kidney disease-beneficial effects by DPP-4 inhibitors.
    Nangaku M; Wanner C
    Kidney Int; 2021 Feb; 99(2):318-322. PubMed ID: 33509354
    [No Abstract]   [Full Text] [Related]  

  • 13. Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
    Seino Y; Kuwata H; Yabe D
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):102-9. PubMed ID: 27186364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
    Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
    Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 17. Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
    Rouette J; Yin H; Yu OHY; Bouganim N; Platt RW; Azoulay L
    Diabet Med; 2020 May; 37(5):868-875. PubMed ID: 32124472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 19. Incretin therapy and its effect on body weight in patients with diabetes.
    Lind M
    Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination pharmacotherapy with incretins: what works best and when?
    Over RK; Ratner RE
    Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.